MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Instil Bio, Inc. (NASDAQ: TIL)*
Organization & Developments: Instil Bio
Parents
Instil Bio, Inc. (NASDAQ: TIL)*
Children
*Founded to develop treatments using a cell therapy approach of autologous tumor infiltrating lymphocytes.
*The firm is a clinical stage biopharma developing treatments for melanoma and other cancer conditions.
2022: Sensei and Instil Bio let go large chunks of workforces, shift pipelines
2023: Instil Bio takes the ax to its lead asset, cutting 60% of its staff in the proces
2024: Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
2024: Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity
2025: Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
2025: Instil Bio: Time To Hop On The Summit Wave?
2025: Instil Bio's Dual-Action Cancer Drug Advances to Clinical Trials for Hard-to-Treat Tumors
2025: Instil Bio's Lung Cancer Drug Achieves 23% Response Rate in Phase 2 Trial, Major Results Expected in Late 2025
2025: Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Jumps
*Key People: Instil Bio
Finance & Acquisitions: Instil Bio